Lyell Immunopharma Statistics
Total Valuation
LYEL has a market cap or net worth of $269.80 million. The enterprise value is $88.40 million.
| Market Cap | 269.80M |
| Enterprise Value | 88.40M |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LYEL has 24.51 million shares outstanding. The number of shares has increased by 49.16% in one year.
| Current Share Class | 24.51M |
| Shares Outstanding | 24.51M |
| Shares Change (YoY) | +49.16% |
| Shares Change (QoQ) | +6.80% |
| Owned by Insiders (%) | 7.26% |
| Owned by Institutions (%) | 36.58% |
| Float | 12.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9,992.65 |
| Forward PS | 16,894.28 |
| PB Ratio | 1.10 |
| P/TBV Ratio | 1.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3,274.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.36, with a Debt / Equity ratio of 0.20.
| Current Ratio | 5.36 |
| Quick Ratio | 5.12 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -93.28% and return on invested capital (ROIC) is -37.53%.
| Return on Equity (ROE) | -93.28% |
| Return on Assets (ROA) | -34.18% |
| Return on Invested Capital (ROIC) | -37.53% |
| Return on Capital Employed (ROCE) | -70.21% |
| Weighted Average Cost of Capital (WACC) | 3.39% |
| Revenue Per Employee | $168 |
| Profits Per Employee | -$1.54M |
| Employee Count | 161 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.56% in the last 52 weeks. The beta is -0.05, so LYEL's price volatility has been lower than the market average.
| Beta (5Y) | -0.05 |
| 52-Week Price Change | -10.56% |
| 50-Day Moving Average | 13.64 |
| 200-Day Moving Average | 19.89 |
| Relative Strength Index (RSI) | 31.08 |
| Average Volume (20 Days) | 114,023 |
Short Selling Information
The latest short interest is 1.13 million, so 4.62% of the outstanding shares have been sold short.
| Short Interest | 1.13M |
| Short Previous Month | 1.15M |
| Short % of Shares Out | 4.62% |
| Short % of Float | 9.33% |
| Short Ratio (days to cover) | 7.30 |
Income Statement
In the last 12 months, LYEL had revenue of $27,000 and -$248.48 million in losses. Loss per share was -$11.82.
| Revenue | 27,000 |
| Gross Profit | 27,000 |
| Operating Income | -190.46M |
| Pretax Income | -248.48M |
| Net Income | -248.48M |
| EBITDA | -180.94M |
| EBIT | -190.46M |
| Loss Per Share | -$11.82 |
Balance Sheet
The company has $204.10 million in cash and $46.60 million in debt, with a net cash position of $181.40 million or $7.40 per share.
| Cash & Cash Equivalents | 204.10M |
| Total Debt | 46.60M |
| Net Cash | 181.40M |
| Net Cash Per Share | $7.40 |
| Equity (Book Value) | 233.82M |
| Book Value Per Share | 9.99 |
| Working Capital | 173.67M |
Cash Flow
In the last 12 months, operating cash flow was -$133.26 million and capital expenditures -$711,000, giving a free cash flow of -$133.97 million.
| Operating Cash Flow | -133.26M |
| Capital Expenditures | -711,000 |
| Depreciation & Amortization | 9.52M |
| Net Borrowing | n/a |
| Free Cash Flow | -133.97M |
| FCF Per Share | -$5.47 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -705,411.11% |
| Pretax Margin | -920,285.19% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LYEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.16% |
| Shareholder Yield | -49.16% |
| Earnings Yield | -92.10% |
| FCF Yield | -49.66% |
Analyst Forecast
The average price target for LYEL is $37.88, which is 244.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $37.88 |
| Price Target Difference | 244.05% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 873.56% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 2, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jun 2, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
LYEL has an Altman Z-Score of -5.88 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.88 |
| Piotroski F-Score | 1 |